We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit
BIOTU

Delisted

BIOTU was delisted on the 2nd of February, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Biotech Acquisition Company Unit in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $540K → $0 (-$540K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
–
Holders Change
-5
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$401K
2
VF
Virtu Financial
New York
-$130K
3
Morgan Stanley
Morgan Stanley
New York
-$5.53K
4
UBS Group
UBS Group
Switzerland
-$2.11K
5
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
1
Millennium Management
New York
– -$401K -40,000 Closed
VF
2
Virtu Financial
New York
– -$130K -12,968 Closed
Morgan Stanley
3
Morgan Stanley
New York
– -$5.53K -551 Closed
UBS Group
4
UBS Group
Switzerland
– -$2.11K -210 Closed
TRCT
5
Tower Research Capital (TRC)
New York
– -$1K -103 Closed

BIOTU Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q1 2023, worth a combined $0 — down 100% from $540K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BIOTU and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Millennium Management, exiting entirely with an estimated $401K sold.

  • 0 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q1 2023, down from 5 in Q4 2022.
  • Funds reported $0 of Biotech Acquisition Company Unit stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Biotech Acquisition Company Unit positions in Q1 2023 and 5 closed out, a net change of -5 holders.
  • The largest Biotech Acquisition Company Unit seller in Q1 2023 was Millennium Management, an estimated $401K sold.

Based on aggregated 13F filings for Q1 2023.